right now, cubicin makes up 9% of the sales. it's a big patent cliff.owever, cubist has a pipeline, including three drugs in phase 3 clinical trials. we are likely to get important data sometime this year two have block buster potential, meaning they can generate over $2 million in sales. it has a pipeline that could be very rewarding. intriguing situation. we need to do more work. which is why i'm thrilled to have michael bonner the ceo to tell us more about his company. tell us more about your company. have a seat. >> thank you very much. >> we are trying, obviously, to get our arms around cubist. >> sure. >> you clearly have one of the biggest drulgs out there. one of the others are on the come right now? >> they are. we are in the last stage before we submit to the regulatory, two antibiotic, one nonantibiotics. we are bullish about two of them. the third is on the need and fits into our beautiful customer structure. that's leverage. >> that's the urinary tract infection and social diarrhea or opioid. >> suppose it's for the urinary tract and intraa

when the hospitals are full of patients with flu many of whom develop pneumonia, cubicin is not a --y whether it's back on track then. here we are, flu season is definitely over. are numbers back on track? >> well certainly we reported a couple weeks ago q 1. we'll report q 2 in july. i think it's safe to say we didn't change our guidance. >> right. >> we had within the range of what we thought was a pretty good first quarter. independent of what the consensus was. and we're very comfortable this year we'll deliver in the u.s. between 900 million and 925 million of cubicin revenue. >> may 7th meeting where we'll hear about a new drug. we have a hearing, you're in a dog fight with a major pharmaceutical company. i expect to hear something pretty much any day, right? this could come down. >> yeah, so what happened was we got notification little over a year ago that hospira filed a challenge with the fda to our patents. what happens in that circumstance is, we sue them to assert our patents. that's a very structured process. the first sort of public part of that process is what's called